Capital & Regional Valuation
Is XC2R undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of XC2R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: XC2R (€0.71) is trading above our estimate of fair value (€0.02)
Significantly Below Fair Value: XC2R is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for XC2R?
Key metric: As XC2R is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is XC2R's PE Ratio? | |
|---|---|
| PE Ratio | 68.2x |
| Earnings | UK£2.10m |
| Market Cap | UK£143.25m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.1x |
| Enterprise Value/EBITDA | 16x |
| PEG Ratio | 1.4x |
Price to Earnings Ratio vs Peers
How does XC2R's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 27.1x | ||
HABA Hamborner REIT | 63.5x | 10.8% | €519.8m |
TRESTATES Trade Estates REIC | 5.2x | n/a | €194.1m |
YORE Olimpo Real Estate SOCIMI | 27.9x | n/a | €195.6m |
VASTB Vastned Belgium | 11.8x | n/a | €143.7m |
XC2R Capital & Regional | 68.2x | 47.8% | €143.2m |
Price-To-Earnings vs Peers: XC2R is expensive based on its Price-To-Earnings Ratio (68.2x) compared to the peer average (27.1x).
Price to Earnings Ratio vs Industry
How does XC2R's PE Ratio compare vs other companies in the European Retail REITs Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: XC2R is expensive based on its Price-To-Earnings Ratio (68.2x) compared to the European Retail REITs industry average (22.5x).
Price to Earnings Ratio vs Fair Ratio
What is XC2R's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 68.2x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate XC2R's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €0.71 | €0.83 +17.0% | 10.1% | €0.89 | €0.71 | n/a | 3 |
| Nov ’25 | €0.73 | €0.83 +13.8% | 10.1% | €0.89 | €0.71 | n/a | 3 |
| Oct ’25 | €0.75 | €0.83 +10.8% | 10.1% | €0.89 | €0.71 | n/a | 3 |
| Aug ’25 | €0.77 | €0.83 +8.7% | 7.1% | €0.89 | €0.77 | n/a | 2 |
| Jul ’25 | €0.70 | €0.79 +11.6% | 9.4% | €0.89 | €0.71 | n/a | 3 |
| Jun ’25 | €0.68 | €0.81 +18.8% | 9.4% | €0.88 | €0.71 | n/a | 4 |
| May ’25 | €0.56 | €0.80 +43.0% | 8.5% | €0.88 | €0.70 | n/a | 5 |
| Apr ’25 | €0.58 | €0.82 +41.0% | 6.5% | €0.88 | €0.76 | n/a | 5 |
| Mar ’25 | €0.59 | €0.82 +38.3% | 6.5% | €0.88 | €0.76 | n/a | 5 |
| Feb ’25 | €0.61 | €0.82 +32.7% | 6.5% | €0.88 | €0.76 | n/a | 5 |
| Jan ’25 | €0.65 | €0.81 +25.3% | 8.4% | €0.92 | €0.75 | n/a | 5 |
| Dec ’24 | €0.64 | €0.82 +29.0% | 8.4% | €0.93 | €0.75 | n/a | 5 |
| Nov ’24 | €0.59 | €0.82 +39.8% | 9.1% | €0.93 | €0.75 | €0.73 | 4 |
| Oct ’24 | €0.61 | €0.82 +34.1% | 9.1% | €0.93 | €0.75 | €0.75 | 4 |
| Sep ’24 | €0.65 | €0.82 +27.5% | 5.3% | €0.87 | €0.76 | €0.77 | 4 |
| Aug ’24 | €0.64 | €0.83 +29.3% | 5.3% | €0.88 | €0.76 | €0.77 | 4 |
| Jul ’24 | €0.64 | €0.83 +29.3% | 5.3% | €0.88 | €0.76 | €0.70 | 4 |
| Jun ’24 | €0.64 | €0.80 +24.6% | 8.3% | €0.86 | €0.69 | €0.68 | 4 |
| May ’24 | €0.60 | €0.79 +32.0% | 7.4% | €0.85 | €0.68 | €0.56 | 5 |
| Apr ’24 | €0.64 | €0.79 +24.7% | 7.4% | €0.85 | €0.68 | €0.58 | 5 |
| Mar ’24 | €0.60 | €0.78 +30.3% | 7.4% | €0.84 | €0.67 | €0.59 | 5 |
| Feb ’24 | €0.61 | €0.80 +30.7% | 7.9% | €0.85 | €0.68 | €0.61 | 5 |
| Jan ’24 | €0.66 | €0.82 +25.0% | 8.2% | €0.86 | €0.69 | €0.65 | 5 |
| Dec ’23 | €0.59 | €0.82 +37.6% | 8.2% | €0.86 | €0.69 | €0.64 | 5 |
| Nov ’23 | €0.53 | €0.82 +54.4% | 8.2% | €0.86 | €0.69 | €0.59 | 5 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Argan
€1.7b
Engages in designing, building, developing, owning, leasing, and managing logistical platforms in France.
871
€65.00
7D
-0.8%
1Y
-14.8%
Allied Properties Real Estate Investment Trust
CA$2.6b
Allied is a leading owner-operator of distinctive urban workspace in Canada's major cities.
5G8
CA$12.18
7D
0.5%
1Y
2.1%
Mercialys
€988.7m
Mercialys is one of France’s leading real estate companies.
M8Y
€10.60
7D
1.1%
1Y
23.9%